China
Medizinprodukt-Marktintelligenz für China. Regulatorische Änderungen, Wettbewerber und Beschaffungstrends.
Länder-Tabelle zuletzt: 9. Aug. 2026 (kann veraltet sein). 7-Tage-Zahl ist live neu berechnet. Tabellenwert war 341.
Signale der letzten 7 Tage
IceCure Medical Receives Regulatory Approval to Market ProSense® in China - PR Newswire
Pier 88 Health and Theranica Announce China NMPA Approval of the Nerivio® REN wearable for Acute Treatment of Migraine - PR Newswire
Nouryon Receives China Nmpa Approval For Cekol Cmc-Na Pharmaceutical Excipient - TradingView
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - BioSpace
Sofwave Receives NMPA Approval in Mainland China - The Manila Times
China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy - PR Newswire APAC - PR Newswire Asia
Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors - CancerNetwork
China Grants First Approval For Plasmid-Based Gene Therapy - insights.citeline.com
China NMPA sets framework for direct role in national R&D funding - AllSci
Harbour BioMed Secures China IND Approval for HBM7004 Bispecific Antibody in Advanced Solid Tumours - BioPharma APAC